Patterns of referral and uptake of BReast CAncer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand

被引:0
作者
Fraser, Katherine [1 ]
Tan, Ai Ling [2 ]
Innes, Carrie [1 ]
Stephens, Rosalie [3 ]
Tristram, Amanda [4 ]
Petrich, Simone [5 ]
Lintott, Caroline [6 ]
Sykes, Peter H. [7 ,8 ]
Gamet, Kimberley [9 ]
Christian, Alice [10 ]
Simcock, Bryony [7 ,8 ]
机构
[1] Univ Otago, Christchurch, New Zealand
[2] Auckland Dist Hlth Board, Natl Womens Hlth, Auckland, New Zealand
[3] Auckland Dist Hlth Board, Auckland, New Zealand
[4] Wellington Hosp, Obstet & Gynaecol, Wellington, New Zealand
[5] Dunedin Publ Hosp, Dunedin, New Zealand
[6] Genet Hlth Serv NZ, Southern Hub, Christchurch, New Zealand
[7] Univ Otago, Dept Obstet & Gynaecol, Christchurch, New Zealand
[8] Christchurch Womens Hosp, Christchurch, New Zealand
[9] Genet Hlth Serv NZ, Northern Hub, Auckland, New Zealand
[10] Genet Hlth Serv NZ, Cent Hub, Wellington, New Zealand
关键词
RISK-ASSESSMENT; SUSCEPTIBILITY; THERAPY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AIMS: To determine the proportion of eligible patients with high-grade serous carcinoma of the ovary, fallopian tube or peritoneum discussed at gynaecological oncology multidisciplinary meetings (MDMs) in New Zealand and subsequently referred for genetic counselling and BRCA pathogenic variant testing. METHODS: Eligible cases were identified from Auckland, Wellington, Christchurch and Dunedin gynaecologic oncology MDM databases between 1 January 2015 to 31 December 2016. Patients who met the eligibility criteria for genetics referral were identified, and cross-referenced against genetic services databases to ascertain the rates of referrals received, the numbers attending appointments, genetic testing offered and range of results. RESULTS: During the two-year period, 205 patients were eligible for referral. Of these, 143 (70%) patients were referred for genetic counselling with 128 (90%) of this group recommended for BRCA pathogenic variant testing. Of the 126 who undertook the test, results were available for 120 (95%). Nineteen patients (16%) tested positive for a germline BRCA pathogenic variant. CONCLUSIONS: The New Zealand rate of referral to genetic counselling for women with high-grade serous cancer, (HGSC), of the ovary, fallopian tube or peritoneum diagnosed between 2015-2016 is encouraging when compared with others internationally. The rate of BRCA positive pathogenic variants is comparable to international data.
引用
收藏
页码:26 / 35
页数:10
相关论文
共 26 条
[1]   BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].
Alsop, Kathryn ;
Fereday, Sian ;
Meldrum, Cliff ;
deFazio, Anna ;
Emmanuel, Catherine ;
George, Joshy ;
Dobrovic, Alexander ;
Birrer, Michael J. ;
Webb, Penelope M. ;
Stewart, Colin ;
Friedlander, Michael ;
Fox, Stephen ;
Bowtell, David ;
Mitchell, Gillian .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663
[2]  
[Anonymous], 2013, CANC NEW REGISTRATIO, P2016
[3]  
[Anonymous], 1993, 978478286410 HUM RIG
[4]  
[Anonymous], COCHRANE DATABASE SY
[5]   Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review [J].
Arts-de Jong, Marieke ;
de Bock, Geertruida H. ;
van Asperen, Christi J. ;
Mourits, Marian J. E. ;
de Hullu, Joanne A. ;
Kets, C. Marleen .
EUROPEAN JOURNAL OF CANCER, 2016, 61 :137-145
[6]   A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment [J].
Bednar, Erica M. ;
Oakley, Holly D. ;
Sun, Charlotte C. ;
Burke, Catherine C. ;
Munsell, Mark F. ;
Westin, Shannon N. ;
Lu, Karen H. .
GYNECOLOGIC ONCOLOGY, 2017, 146 (02) :399-404
[7]   Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing [J].
Cohen, Paul A. ;
Nichols, Cassandra B. ;
Schofield, Lyn ;
Van Der Werf, Steven ;
Pachter, Nicholas .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (05) :892-897
[8]   Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Coleman, Robert L. ;
Oza, Amit M. ;
Lorusso, Domenico ;
Aghajanian, Carol ;
Oaknin, Ana ;
Dean, Andrew ;
Colombo, Nicoletta ;
Weberpals, Johanne, I ;
Clamp, Andrew ;
Scambia, Giovanni ;
Leary, Alexandra ;
Holloway, Robert W. ;
Amenedo Gancedo, Margarita ;
Fong, Peter C. ;
Goh, Jeffrey C. ;
O'Malley, David M. ;
Armstrong, Deborah K. ;
Garcia-Donas, Jesus ;
Swisher, Elizabeth M. ;
Floquet, Anne ;
Konecny, Gottfried E. ;
McNeish, lain A. ;
Scott, Clare L. ;
Cameron, Terri ;
Maloney, Lara ;
Isaacson, Jeff ;
Goble, Sandra ;
Grace, Caroline ;
Harding, Thomas C. ;
Raponi, Mitch ;
Sun, James ;
Lin, Kevin K. ;
Giordano, Heidi ;
Ledermann, Jonathan A. .
LANCET, 2017, 390 (10106) :1949-1961
[9]   Keeping it simple: Genetics referrals for all invasive serous ovarian cancers [J].
Demsky, R. ;
McCuaig, J. ;
Maganti, M. ;
Murphy, K. J. ;
Rosen, B. ;
Armel, S. R. .
GYNECOLOGIC ONCOLOGY, 2013, 130 (02) :329-333
[10]   Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction [J].
Heemskerk-Gerritsen, B. A. M. ;
Seynaeve, C. ;
van Asperen, C. J. ;
Ausems, M. G. E. M. ;
Collee, J. M. ;
van Doorn, H. C. ;
Garcia, E. B. Gomez ;
Kets, C. M. ;
van Leeuwen, F. E. ;
Meijers-Heijboer, H. E. J. ;
Mourits, M. J. E. ;
van Os, T. A. M. ;
Vasen, H. F. A. ;
Verhoef, S. ;
Rookus, M. A. ;
Hooning, M. J. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (05)